Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial

International Journal of Dermatology

Volumn 45, Issue 5, 2006, Pages 605-614

  Papp, Kim A ^{a,b,c,d,e,f,g,h}   Bressinck, Reni ^{a,b,c,d,e,f,g,h}   Fretzin, Scott ^{a,b,c,d,e,f,g,h}   Goffe, Bernard ^{a,b,c,d,e,f,g,h}   Kempers, Steven ^{a,b,c,d,e,f,g,h}   Gordon, Kenneth B ^{a,b,c,d,e,f,g,h}   Caro, Ivor ^{a,b,c,d,e,f,g,h}   Walicke, Patricia A ^{a,b,c,d,e,f,g,h}   Wang, Xiaolin ^{a,b,c,d,e,f,g,h}   Menter, Alan ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Minor and James Medical   (United States)

^e Minnesota Clinical Study Center   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g GENENTECH INC   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CHILL; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; ONTARIO; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646167222     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02777.x     Document Type: Article

References (28)

1. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61: 11-21.
2. Kuijpers ALA, van de Kerkhof PCM. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2000; 1: 27-39.
3. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623-629.
4. Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 2004; 150: 11-23.
5. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
6. Orfanos CE. Treatment of psoriasis with retinoids: Present status. Cutis 1999; 64: 347-353.
7. Menter MA, Abramovits W. Rational, sequential and combination regimens in the treatment of psoriasis. Derm Ther 1999; 11: 88-95.
8. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-459.
9. Pariser DM. Improving the standard of care for patients with psoriasis. Manage Care Suppl 2003; 12: 18-20.
10. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151: 3-17.
11. Gottlieb AB, Miller B, Lowe N, et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003; 7: 198-207.
12. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-435.
13. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591-600.
14. Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-674.
15. Lebwohl M, Tyring S, Hamilton T, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
16. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis. A randomized controlled trial. JAMA 2003; 290: 3073-3080.
17. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized Phase III trial. J Am Acad Dermatol 2005; 52: 425-433.
18. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38.
19. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3: 614-624.
20. Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 4.
21. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003; 49: S105-S111.
22. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49: S87-S97.
23. Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000; 115: 333.
24. Gottlieb AB, Lebwohl M, Totoritis MC, et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 2002; 47: 692-700.
25. Raptiva™ (efalizumab) [package insert] South San Francisco, CA: Genentech, Inc., 2003.
26. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
27. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
28. Menter A, Hamilton TK, Caro I, et al. Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label Phase IIIb multicenter trial. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2793.